4. Health-related quality of life in transplant noneligible newly diagnosed multiple myeloma patients treated with melphalan/prednisolone plus either thalidomide or lenalidomide; results of the HOVON87/NMSG18 study

Activity: Talks and presentationsConference presentations

Period8. Sep 2017
Event typeSeminar
LocationTrondheim, Norway